Hugh Mostafid

Hugh Mostafid

Auto-generated profile, based on publicly available information

Hugh Mostafid

Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in European Urology
Verified
Journal Article
Closed access
MBMarko Babjuk
Marko Babjuk
MBMaximilian Burger
Maximilian Burger
ECEva M. Compérat
Eva M. Compérat
PGPaolo Gontero
Paolo Gontero
AMA. Hugh Mostafid
A. Hugh Mostafid
VSViktor Soukup
Viktor Soukup

1 February 2020 in European Urology
Verified
Journal Article
Open access
JWJ. Alfred Witjes
J. Alfred Witjes
MBMarek Babjuk
Marek Babjuk
JBJoaquim Bellmunt
Joaquim Bellmunt
HBH. Maxim Bruins
H. Maxim Bruins
TRTheo M. De Reijke
Theo M. De Reijke
AHAlan Horwich
Alan Horwich
Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Online Delphi survey and consensus conference. The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.


1 March 2019 in European Urology Focus
Verified
Journal Article
Closed access
JDJose Luis Dominguez-Escrig
Jose Luis Dominguez-Escrig
BPBenoit Peyronnet
Benoit Peyronnet
TSThomas Seisen
Thomas Seisen
HBHarman M. Bruins
Harman M. Bruins
YYYuhong Yuan
Yuhong Yuan
MRMorgan Rouprêt
Morgan Rouprêt

1 October 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NANicola E. Annels
Nicola E. Annels
DMDavid Mansfield
David Mansfield
MAMehreen Arif
Mehreen Arif
CBCarmen Ballesteros-Merino
Carmen Ballesteros-Merino
GSGuy R. Simpson
Guy R. Simpson
HPHardev Pandha
Hardev Pandha
Purpose: The CANON [CAVATAK in NON–muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer.Patients and Methods: Fifteen patients enrolled in this “window of opportunity” phase I study, exposing primary bladder cancers to CAVATAK prior to surgery. The first 9 patients received intravesical administration of monotherapy CAVATAK; in the second stage, 6 patients received CAVATAK with a subtherapeutic dose of mitomycin C, known to enhance expression of ICAM-1 on bladder cancer cells. The primary endpoint was to determine patient safety and maximum tolerated dose (MTD). Secondary endpoints were evidence of viral replication, induction of inflammatory cytokines, antitumor activity, and viral-induced changes in resected tissue.Results: Clinical activity of CAVATAK was demonstrated by induction of tumor inflammation and hemorrhage following either single or multiple administrations of CAVATAK in multiple patients, and a complete resolution of tumor in 1 patient. Whether used alone or in combination with mitomycin C, CAVATAK caused marked inflammatory changes within NMIBC tissue biopsies by upregulating IFN-inducible genes, including both immune checkpoint inhibitory genes (PD-L1 and LAG3) and Th1-associated chemokines, as well as the induction of the innate activator RIG-I, compared with bladder cancer tissue from untreated patients. No significant toxicities were reported in any patient, from either virus or combination therapy.Conclusions: The acceptable safety profile of CAVATAK, proof of viral targeting, replication, and tumor cell death together with the virus-mediated increases in “immunological heat” within the tumor microenvironment all indicate that CAVATAK may be potentially considered as a novel therapeutic for NMIBC.

1 July 2018 in European Urology
Verified
Journal Article
Closed access
WTWei Shen Tan
Wei Shen Tan
AFAndrew Feber
Andrew Feber
RSRachael Sarpong
Rachael Sarpong
PKPramit Khetrapal
Pramit Khetrapal
SRSimon Rodney
Simon Rodney
JKJohn D. Kelly
John D. Kelly